{"id":"ee2473e8-adb9-53b5-b550-5ed0b26aa930","stable_key":"1b599eb7-b22a-5fda-bcf0-9d92b5ae1311:gb-duration-drives-the-field-loss","predicate":"causes","statement":"Out of 88 patients exposed to vigabatrin in infancy, 28 were able to perform formal visual field testing, mild vigabatrin-attributed visual field defect was found in four patients and severe defect in one, median vigabatrin treatment duration for those with normal visual field was 11 months compared to 19 months for those with the defect, optical coherence tomography showed concomitant attenuated retinal nerve fiber layer in three children, and the overall prevalence after exposure in infancy is lower than the 52% which has been reported after exposure in adulthood while the risk increases with longer treatment duration.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"16a77c82-4b54-52f5-a52f-a47fbfc70a86","mechanism_event_label":"The drug that raises brain GABA costs some patients their peripheral vision, and the longer they take it the likelier that is.","subject":{"id":"694d1817-618d-5b0f-9222-cccdf2a43b31","slug":"vigabatrin","display_name":"Vigabatrin","entity_type_key":"small_molecule"},"object":{"id":"0dc59c86-833b-5d9f-8f8a-476ef08dfba8","slug":"vigabatrin-visual-field-defect","display_name":"Vigabatrin-attributed visual field defect","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"16a77c82-4b54-52f5-a52f-a47fbfc70a86","stable_key":"1b599eb7-b22a-5fda-bcf0-9d92b5ae1311:gb-duration-drives-the-field-loss-event","event_type":"observed_intervention","label":"The drug that raises brain GABA costs some patients their peripheral vision, and the longer they take it the likelier that is.","description":"Out of 88 patients exposed to vigabatrin in infancy, 28 were able to perform formal visual field testing, mild vigabatrin-attributed visual field defect was found in four patients and severe defect in one, median vigabatrin treatment duration for those with normal visual field was 11 months compared to 19 months for those with the defect, optical coherence tomography showed concomitant attenuated retinal nerve fiber layer in three children, and the overall prevalence after exposure in infancy is lower than the 52% which has been reported after exposure in adulthood while the risk increases with longer treatment duration.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"5fc1034c-13a1-5941-a939-f9ca46ba526b","slug":"retinal-nerve-fibre-layer","display_name":"Peripapillary retinal nerve fibre layer thickness","entity_type_key":"cellular_process"},"role":"thinned_structure","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9ef4e03f-a3be-55c6-90cb-4db1381e340c","slug":"human-abat","display_name":"Human GABA transaminase / ABAT","entity_type_key":"protein"},"role":"inhibited_enzyme","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"694d1817-618d-5b0f-9222-cccdf2a43b31","slug":"vigabatrin","display_name":"Vigabatrin","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"0dc59c86-833b-5d9f-8f8a-476ef08dfba8","slug":"vigabatrin-visual-field-defect","display_name":"Vigabatrin-attributed visual field defect","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/gaba-research/34716587.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"30459a805ac23ba0a6f0cb4c9484da96a968609466a4bb1fc7c41636542ba887\", \"start_char\": 0, \"end_char\": 1403, \"text_sha256\": \"30459a805ac23ba0a6f0cb4c9484da96a968609466a4bb1fc7c41636542ba887\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Retrospective population-based perimetry and optical coherence tomography at school age in children exposed in infancy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Vigabatrin given for infantile spasms, with visual fields and retinal nerve fibre layer measured years later","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Only 28 of 88 exposed patients could perform formal visual field testing, which limits the prevalence estimate in both directions.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in.","comparator":null,"unit":null,"notes":"","entity":{"slug":"gaba","display_name":"Gamma-aminobutyric acid","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The drug that raises brain GABA costs some patients their peripheral vision, and the longer they take it the likelier that is.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[gb-p34716587] Visual field defects after vigabatrin treatment during infancy: retrospective population-based study. (2022). https://pubmed.ncbi.nlm.nih.gov/34716587/ DOI: 10.1111/dmcn.15099","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Retina","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"5782623a-8c90-5383-ac0d-51ff76974423","evidence_kind":"source_excerpt","locator":"Lines 170-181","start_line":170,"end_line":181,"excerpt":"### gb-duration-drives-the-field-loss\nOut of 88 patients exposed to vigabatrin in infancy, 28 were able to perform formal visual field testing, mild vigabatrin-attributed visual field defect was found in four patients and severe defect in one, median vigabatrin treatment duration for those with normal visual field was 11 months compared to 19 months for those with the defect, optical coherence tomography showed concomitant attenuated retinal nerve fiber layer in three children, and the overall prevalence after exposure in infancy is lower than the 52% which has been reported after exposure in adulthood while the risk increases with longer treatment duration.\nCondition category: normal\nnutrient_topic: GABA research collection; topical membership is not evidence of a direct clinical effect, and the sign of a GABA response depends on the chloride gradient of the cell it was measured in.\nplain_language: The drug that raises brain GABA costs some patients their peripheral vision, and the longer they take it the likelier that is.\norganism: Human\ntissue_or_cell_type: Retina\nexperimental_model: Retrospective population-based perimetry and optical coherence tomography at school age in children exposed in infancy\nlimitations: Only 28 of 88 exposed patients could perform formal visual field testing, which limits the prevalence estimate in both directions.\nexposure: Vigabatrin given for infantile spasms, with visual fields and retinal nerve fibre layer measured years later\nevidence_span: {\"source_cache\": \"artifacts/gaba-research/34716587.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"30459a805ac23ba0a6f0cb4c9484da96a968609466a4bb1fc7c41636542ba887\", \"start_char\": 0, \"end_char\": 1403, \"text_sha256\": \"30459a805ac23ba0a6f0cb4c9484da96a968609466a4bb1fc7c41636542ba887\"}\n[gb-p34716587] Visual field defects after vigabatrin treatment during infancy: retrospective population-based study. (2022). https://pubmed.ncbi.nlm.nih.gov/34716587/ DOI: 10.1111/dmcn.15099","model_system":"Retrospective population-based perimetry and optical coherence tomography at school age in children exposed in infancy","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [gb-p34716587] Visual field defects after vigabatrin treatment during infancy: retrospective population-based study. (2022). https://pubmed.ncbi.nlm.nih.gov/34716587/ DOI: 10.1111/dmcn.15099","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"197c25bb-45fa-5e97-b3ab-2d2eff4e0d0a","stable_key":"import-1b599eb7-b22a-5fda-bcf0-9d92b5ae1311","title":"GABA: a ligand with no sign of its own, the cofactor that limits its synthesis, the barrier that keeps it out of the brain, and the immune settings where the same molecule protects and harms (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"07e36027ff70dbbe5563cddfa4758fd9b9b6eec148faecccafd476900b770456","revision_id":"a12d61de-f189-5bda-af3d-f31a1e61bccf","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}